A detailed history of Wolverine Asset Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wolverine Asset Management LLC holds 46,500 shares of BMY stock, worth $2.73 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
46,500
Previous 81,600 43.01%
Holding current value
$2.73 Million
Previous $3.39 Million 28.98%
% of portfolio
0.06%
Previous 0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$40.25 - $52.99 $161,966 - $213,231
4,024 New
4,024 $167,000
Q4 2023

Feb 01, 2024

SELL
$48.48 - $57.85 $772,819 - $922,186
-15,941 Reduced 32.71%
32,788 $1.68 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $291,881 - $326,368
5,042 Added 11.54%
48,729 $2.83 Million
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $653,983 - $726,146
-10,265 Reduced 19.03%
43,687 $2.79 Million
Q1 2023

May 08, 2023

BUY
$65.71 - $74.53 $1.16 Million - $1.32 Million
17,674 Added 48.72%
53,952 $3.74 Million
Q4 2022

Feb 01, 2023

BUY
$68.48 - $81.09 $2.48 Million - $2.94 Million
36,278 New
36,278 $2.61 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $175,490 - $194,054
-3,933 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $13 Million - $15.5 Million
-287,875 Reduced 98.65%
3,933 $187,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $3.63 Million - $4.71 Million
74,430 Added 34.24%
291,808 $15.2 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $1.93 Million - $2.18 Million
35,014 Added 19.2%
217,378 $13.5 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $6.55 Million - $8.17 Million
129,681 Added 246.15%
182,364 $10.1 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $3.16 Million - $3.63 Million
52,683 New
52,683 $3.33 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wolverine Asset Management LLC Portfolio

Follow Wolverine Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Asset Management LLC with notifications on news.